Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06375512 · ClinicalTrials.gov registry record · Phase 1
A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
A Phase 1 study of Herpes Zoster, sponsored by Shenzhen Shenxin Biotechnology Co..
- Active
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
- 3
- Study locations
NCT06375512 is a Phase 1 study of Herpes Zoster that is active but no longer recruiting, run by Shenzhen Shenxin Biotechnology Co.. The registered enrollment target is 150 participants, below the 2,164-participant average among 16 other Herpes Zoster trials with a reported enrollment target (93% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT06375512, a Phase 1 study of Herpes Zoster, is active but no longer recruiting, sponsored by Shenzhen Shenxin Biotechnology Co..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
- 3
- Study locations
Study Summary
The study will evaluate the safety, tolerability, and immunogenicity (your immune system's reaction) of the study vaccine called Herpes Zoster IN001 mRNA Vaccine (IN001) in healthy participants who are between 50 and 69 years of age
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Shingrix
- BIOLOGICAL HZ Vaccine (IN001)
Study Locations (3)
Florida
- CenExel - Hollywood
New South Wales
- Emeritus Research Pty Ltd - Sydney
Victoria
- Emeritus Research Pty Ltd - Melbourne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-07-05 |
| Est. Completion | 2026-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06375512
The ClinicalTrials.gov registry entry for NCT06375512 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,164-participant average among 16 other Herpes Zoster trials with a reported enrollment target (93% lower). The listed sponsor is Shenzhen Shenxin Biotechnology Co., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Herpes Zoster appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06375512 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, New South Wales, Victoria.
Frequently Asked Questions
What is clinical trial NCT06375512 about?
NCT06375512 is a clinical study titled "A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants". The study will evaluate the safety, tolerability, and immunogenicity (your immune system's reaction) of the study vaccine called Herpes Zoster IN001 mRNA Vaccine (IN001) in healthy participants who are between 50 and 69 years of age
What is the current status of trial NCT06375512?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2024-07-05. Estimated completion is 2026-06.
What conditions does trial NCT06375512 study?
This clinical trial studies the following conditions: Herpes Zoster.
What interventions are being tested in trial NCT06375512?
The interventions under investigation include: Placebo (BIOLOGICAL), Shingrix (BIOLOGICAL), HZ Vaccine (IN001) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06375512?
This trial is sponsored by Shenzhen Shenxin Biotechnology Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06375512 being conducted?
This trial has 3 study locations across Florida, New South Wales, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Herpes Zoster
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age
ACTIVE NOT RECRUITING · Phase 1
-
Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds
COMPLETED · Phase 1
-
Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects
COMPLETED · Phase 1
-
Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions
ACTIVE NOT RECRUITING
-
Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.